Trinseo sees FY25 adjusted EBITDA $167M-$177M

Commenting on the full year outlook, Bozich said, “We anticipate Adjusted EBITDA of approximately $30 million to $40 million and sequentially better free cash flow for the fourth quarter. This forecast assumes a continuation of the higher level in demand in our formulated products through November, but an exaggerated seasonal effect in December. We will remain intensely focused on what is in our control, including improving our free cash flow in the short and long term through working capital management, restructuring activities and other actions.”